Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orca-T in advanced hematologic malignancies
NCT05316701Phase 3Active, not recruiting
- Sponsor
- Orca Bio
- Start
- Jun 2022
- Primary completion
- Jul 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), mixed phenotype acute leukemia (MPAL), acute undifferentiated leukemia (AML-M0), myelodysplastic syndrome (MDS), sponsored by Orca Bio. Started Jun 2022; status: active, not recruiting.
02
Drugs
allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)acute undifferentiated leukemia (AML-M0)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05316701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05316701.